OpGen (NASDAQ:OPGN) announced today that it has introduced a Research Use Only (RUO) Acuitas® AMR Gene Panel u5.47 test for commercial sale. The Acuitas AMR Gene Panel u5.47 test was developed to detect the most common bacterial causes of cUTI directly from urine (E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis, E. faecalis) and isolated colonies. …

OpGen (NASDAQ:OPGN) announced today that it has introduced a Research Use Only (RUO) Acuitas® AMR Gene Panel u5.47 test for commercial sale. The Acuitas AMR Gene Panel u5.47 test was developed to detect the most common bacterial causes of cUTI directly from urine (E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis, E. faecalis) and isolated colonies.

As quoted in the press release:

The RUO Acuitas AMR Gene Panel u5.47 detects over 600 multidrug-resistance genetic subtypes as predictors of resistance to the following antibiotic classes: Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Polymyxins, Penicillins, Sulfonamides, Trimethoprim and Vancomycin. Test results are available in under three hours compared with traditional microbiology methods, which can take two to three days to provide results.

Click here to read the full press release.